Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Joshua A. Hill(Seattle Pacific University), Cameron J. Turtle(The University of Sydney)
Cited by 564
Related Papers
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|Blood|2016|743
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
|Nature Biotechnology|2017|623
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
|Blood|2019|399
Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance
|The Journal of Experimental Medicine|1998|340